Prostate Cancer
Theranostics Transforming Prostate Cancer Care
Prostate cancer is currently one of the most established areas for theranostics.
Advances in Prostate-Specific Membrane Antigen (PSMA) imaging and radioligand therapy have helped improve the identification and management of prostate cancer for selected patients.
Treatments
Theranostic approaches may involve:
-
PSMA PET imaging
-
PSMA-targeted radioligand therapies
-
Monitoring of treatment response through molecular imaging
Treatment suitability depends on individual patient circumstances and specialist assessment.
Research
Research continues to investigate:
-
Earlier use of PSMA-targeted therapies
-
Combination treatment approaches
-
New imaging and therapeutic targets
Patient Guide
Patients with prostate cancer who are interested in theranostics should discuss available imaging and treatment options with their healthcare team.
Learn More
Cancer Council Australia:
https://www.cancer.org.au/cancer-information/types-of-cancer/prostate-cancer
Prostate Cancer Foundation of Australia:
https://www.pcfa.org.au
Frequently Asked Questions
Can theranostics be used for every cancer type?
Is theranostics only used in cancer?
How do I know if my cancer may be suitable for theranostics?
Continue Exploring
Frequently Asked Questions
Explore answers to some of the most common questions about theranostics, precision medicine and targeted cancer care.
Stay Connected
Join our community to receive educational resources, industry updates, event invitations and the latest developments in theranostics.
Medical Disclaimer
The information provided on this website is intended for educational purposes only and should not be considered medical advice. Treatment decisions should always be made in consultation with qualified healthcare professionals who can consider individual circumstances and clinical needs.